Genetic Technologies' BrevaGen
This article was originally published in The Gray Sheet
Executive Summary
Breast cancer risk test is acquired through an asset purchase deal with Perlegen Sciences for undisclosed terms. Announced April 14, the deal will allow Genetic Technologies to launch the test in the U.S. and Australia in the second half of 2010, the firm says. The test combines population risk factors based on the Gail Score with validated genetic risk factors to measure non-familial, sporadic risk of breast cancer for women where a breast biopsy outcome is indeterminate, the company explains. "This product fulfils an unmet need by better classifying women at moderate risk of breast cancer who would potentially benefit from preventive therapy or more intensive monitoring." The firm estimates the potential U.S. market at up to $400 million-$500 million
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.